NCT03207399

Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment

Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment: A Pilot Feasibility and Efficacy Study

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Duke University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate whether treatment with Epclusa (sofosbuvir/velpatasvir) after lung transplantation in individuals with chronic hepatitis C infection is feasible, safe and effective at curing HCV.

Conditions

• Hepatitis C, Chronic
• Lung Transplant

Interventions

Type	Name	Description
DRUG	Epclusa	Patients will be treated with this drug for 12 weeks post lung transplant.

Timeline

• Start date: 2017-09-15
• Primary completion: 2019-03-25
• Completion: 2019-03-25
• First posted: 2017-07-02
• Last updated: 2019-09-11
• Results posted: 2019-09-11

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study